首页> 外文OA文献 >Rapid Detection of the ACMG/ACOG-Recommended 23 CFTR Disease-Causing Mutations Using Ion Torrent Semiconductor Sequencing
【2h】

Rapid Detection of the ACMG/ACOG-Recommended 23 CFTR Disease-Causing Mutations Using Ion Torrent Semiconductor Sequencing

机译:使用离子激流半导体测序快速检测ACMG / ACOG推荐的23种CFTR致病突变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cystic fibrosis (CF) is one of the most frequently diagnosed autosomal-recessive diseases in the Caucasian population. For general-population CF carrier screening, the American College of Medical Genetics (ACMG)/American College of Obstetricians and Gynecologists (ACOG) have recommended a core panel of 23 mutations that will identify 49–98% of carriers, depending on ethnic background. Using a genotyping technology that can rapidly identify disease-causing mutations is important for high-throughput general-population carrier screening, confirming clinical diagnosis, determining treatment options, and prenatal diagnosis. Here, we describe a proof-of-concept study to determine whether the Ion Torrent Personal Genome Machine (PGM) sequencer platform can reliably identify all ACMG/ACOG 23 CF transmembrane conductance regulator (CFTR) mutations. A WT CF specimen along with mutant DNA specimens representing all 23 CFTR mutations were sequenced bidirectionally on the Ion Torrent 314 chip to determine the accuracy of the PGM for CFTR variant detection. We were able to reliably identify all of the targeted mutations except for 2184delA, which lies in a difficult, 7-mer homopolymer tract. Based on our study, we believe PGM sequencing may be a suitable technology for identifying CFTR mutations in the future. However, as a result of the elevated rate of base-calling errors within homopolymer stretches, mutations within such regions currently need to be evaluated carefully using an alternative method.
机译:囊性纤维化(CF)是高加索人群中最常被诊断为常染色体隐性遗传疾病之一。对于普通人群CF携带者的筛查,美国医学遗传学院(ACMG)/美国妇产科学院(ACOG)推荐了一个由23个突变组成的核心小组,根据种族背景,这些突变将确定49-98%的携带者。使用能够快速识别引起疾病的突变的基因分型技术对于高通量普通人群携带者筛查,确定临床诊断,确定治疗方案和产前诊断非常重要。在这里,我们描述了一项概念验证研究,以确定离子激流个人基因组机(PGM)测序仪平台能否可靠地识别所有ACMG / ACOG 23 CF跨膜电导调节剂(CFTR)突变。 WT CF标本以及代表所有23个CFTR突变的突变DNA标本在Ion Torrent 314芯片上双向测序,以确定PGM用于CFTR变异检测的准确性。我们能够可靠地鉴定除2184delA以外的所有靶向突变,该突变位于困难的7聚体均聚物链中。根据我们的研究,我们相信PGM测序可能是将来识别CFTR突变的合适技术。但是,由于均聚物拉伸中碱基检出错误率升高,目前需要使用替代方法仔细评估此类区域内的突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号